Evidence check: COMT in the context of menopause

COMT (catechol-O-methyltransferase) is an enzyme involved in breaking down catecholamines (e.g., dopamine, adrenaline) and estrogen metabolites. During menopause, declining estrogen levels may theoretically increase the relevance of COMT variants for mood, cognition, and oxidative stress. The common rs4680 (Val158Met) polymorphism affects enzyme activity: Met carriers have lower activity, which has been linked to higher stress sensitivity and possibly more severe menopausal symptoms. However, the evidence is weak: most studies are small, conflicting, or purely mechanistic. No robust clinical trials demonstrate that COMT genotyping improves menopause management. Therefore, a DNA test for COMT alone is not clinically actionable for menopause. It may be part of a broader assessment, but lifestyle, hormone levels, and medical guidance remain paramount. Evidence: mechanistic/unclear.